Evidence for the heterotetrameric structure of the adenosine A 2A -dopamine D 2 receptor complex

Biochemical Society Transactions

Volumn 44, Issue 2, 2016, Pages 595-600

  Casadó Anguera, Verònica ^a,b   Bonaventura, Jordi ^b,c   Moreno, Estefanía ^a,b   Navarro, Gemma ^a,b   Cortés, Antoni ^a,b   Ferré, Sergi ^c   Casadó, Vicent ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Adenosine receptors; Allosteric modulation; Dopamine receptors; G protein coupled receptor (GPCR); Heteromerization; Homodimerization

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; DIMER; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HOMODIMER; OLIGOMER; TETRAMER; LIGAND;

ALLOSTERISM; BINDING AFFINITY; COMPLEX FORMATION; CORPUS STRIATUM; EX VIVO STUDY; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; HUMAN; METABOLISM;

ALLOSTERIC REGULATION; DIMERIZATION; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2;

EID: 85009818619     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150276     Document Type: Review

References (55)

1. Whorton, M.R., Bokoch, M.P., Rasmussen, S.G., Huang, B., Zare, R.N., Kobilka, B. and Sunahara, R.K. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U.S.A. 104, 7682-7687
2. Chabre, M., Deterre, P. and Antonny, B. (2009) The aparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol. Sci. 30, 182-187
3. Casadó, V., Cortés, A., Mallol, J., Perez-Capote, K., Ferré, S., Lluís, C., Franco, R. and Canela, E.I. (2009) GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol. Ther. 124, 248-257
4. Milligan, G. (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14
5. Ferré, S., Navarro, G., Casadó, V., Cortés, A., Mallol, J., Canela, E.I., Lluis, C. and Franco, R. (2010) G-protein coupled receptor heteromers as new targets for drug development. Prog. Mol. Biol. Transl. Sci. 91, 41-52
6. Ferré, S., Casadó, V., Devi, L.A., Filizola, M, Jockers, R., Lohse, M.J., Milligan, G., Pin, J.P. and Guitart, X. (2014) G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol. Rev. 66, 413-434
7. Ciruela, F., Fernandez-Dueñas, V., Llorente, J., Borroto-Escuela, D., Cuffi, M.L., Carbonell, L., Sanchez, S., Agnati, L.F., Fuxe, K. and Tasca, C.I. (2012) G protein-coupled receptor oligomerization and brain integration: focus on adenosinergic transmission. Brain Res. 1476, 86-95
8. Miller, L.J., Dong, M. and Harikumar, K.G. (2012) Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br. J. Pharmacol. 166, 18-26
9. Steel, E., Murray, V.L. and Liu, A.P. (2014) Multiplex detection by homo-and heterodimerization of g protein-coupled receptors by proximity biotinylation. PLoS One 9, e93646
10. Ferré, S., Baler, R., Bouvier, M., Caron, M.G., Devi, L.A., Durroux, T., Fuxe, K., George, S.R., Javitch, J.A., Lohse, M.J. et al. (2009) Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134
11. Guitart, X., Navarro, G., Moreno, E., Yano, H., Cai, N.S., Sánchez-Soto, M., Kumar-Barodia, S., Naidu, Y.T., Mallol, J., Cortés, A. et al. (2014) Functional selectivity of allosteric interactions within GPCR oligomers: the dopamine D1-D3 receptor heterotetramer. Mol. Pharmacol. 86, 417-429
12. Cristóvão-Ferreira, S., Navarro, G., Brugarolas, M., Pérez-Capote, K., Vaz, S.H., Fattorini, G., Conti, F., Lluís, C., Ribeiro, J.A., McCormick, P.J. et al. (2013) A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal. 9, 433-449
13. Smith, N.J. and Milligan, G. (2010) Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 62, 701-725
14. Casadó, V., Ferrada, C., Bonaventura, J., Gracia, E., Mallol, J., Canela, E.I., Lluís, C., Cortés, A. and Franco, R. (2009) Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem. Pharmacol. 78, 1456-1463
15. Ferré, S., Bonaventura, J., Tomasi, D., Navarro, G., Moreno, E., Cortés, A., Lluís, C., Casadó, V. and Volkow, N.D. (2015) Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Neuropharmacology 4
16. Kenakin, T. and Miller, L.J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304
17. Ferré, S., von Euler, G., Johansson, B., Fredholm, B.B. and Fuxe, K. (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 88, 7238-7241
18. Dasgupta, S., Ferré, S., Kull, B., Hedlund, P.B., Finnman, U.B., Ahlberg, S., Arenas, E., Fredholm, B.B. and Fuxe, K. (1996) Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. Eur. J. Pharmacol. 316, 325-331
19. Diaz-Cabiale, Z., Vivo, M., Del Arco, A., O'Connor, W.T., Harte, M.K., Muller, C.E., Martinez, E., Popoli, P., Fuxe, K. and Ferré, S. (2001) Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striatopallidal GABA pathway in rats: interaction with adenosine A2A and dopamine D2 receptors. Neurosci. Lett. 324, 154-158
20. Kudlacek, O., Just, H., Korkhov, V.M., Vartian, N., Klinger, M., Pankevych, H., Yang, Q., Nanoff, C., Freissmuth, M. and Boehm, S. (2003) The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 28, 1317-1327
21. Bonaventura, J., Navarro, G., Casadó-Anguera, V., Azdad, K., Rea, W., Moreno, E., Brugarolas, M., Mallol, J., Canela, E.I., Lluis, C. et al. (2015) Allosteric interactions between agonists and antagonists within the mechanism adenosine A2A-dopamine D2 receptor heterotetramer. Proc. Natl. Acad. Sci. U.S.A. 11, E3609-E3618
22. Hillion, J., Canals, M., Torvinen, M., Casadó, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M.E., Mallol, J. et al. (2002) Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091-18097
23. Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S.R., Neve, K., Fuxe, K., Agnati, L.F., Woods, A.S. et al. (2003) Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749
24. Azdad, K., Gall, D., Woods, A.S., Ledent, C., Ferré, S. and Schiffmann, S.N. (2009) Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34, 972-986
25. Trifilieff, P., Rives, M.L., Urizar, E., Piskorowski, R.A., Vishwasrao, H.D., Castrillon, J., Schmauss, C., Slättman, M., Gullberg, M and Javitch, J.A. (2011) Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 51, 111-118
26. Fernández-Dueñas, V., Taura, J.J., Cottet, M., Gómez-Soler, M., López-Cano, M., Ledent, C., Watanabe, M., Trinquet, E., Pin, J.P., Luján, R. et al. (2015) Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats. Dis. Model Mech. 8, 57-63
27. Ferré, S., Agnati, L.F., Ciruela, F., Lluis, C., Woods, A.S., Fuxe, K. and Franco, R. (2007) Neurotransmitter receptor heteromers and their integrative role in "local modules": the striatal spine module. Brain Res. Rev. 55, 55-67
28. Ferré, S. (2008) An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 105, 1067-1079
29. Ferré, S., Ciruela, F., Canals, M., Marcellino, D., Burgueño, J., Casadó, V., Hillion, J., Torvinen, M., Fanelli, F., de Benedetti, P. et al. (2004) Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265-271
30. Müller, C.E. and Ferré, S. (2007) Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Pat. CNS Drug Discov. 2, 1-21
31. Armentero, M.T., Pinna, A., Ferré, S., Lanciego, J.L., Muller, C.E. and Franco, R. (2011) Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 132, 280-299
32. Orrú, M., Bakesová, J., Brugarolas, M., Quiroz, C., Beaumont, V., Goldberg, S.R., Lluís, C., Cortés, A., Franco, R., Casadó, V. et al. (2011) Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One 6, e16088
33. Jenner, P. (2014) An overview of adenosine A2A receptor antagonists in Parkinson's disease. Int. Rev. Neurobiol. 119, 71-86
34. Uchida, S., Soshiroda, K., Okita, E., Kawai-Uchida, M., Mori, A., Jenner, P. and Kanda, T. (2015) The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur. J. Pharmacol. 766, 25-30
35. Pinna, A. (2014) Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28, 455-474
36. May, L.T., Leach, K., Sexton, P.M. and Christopoulos, A. (2007) Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51
37. 1 receptors. J. Pharmacol. Exp. Ther. 332, 876-885
38. 2A receptor define ligand efficacy. Mol. Pharmacol. 83, 949-958
39. Doré, A.S., Robertson, N., Errey, J.C., Ng, I., Hollenstein, K., Tehan, B., Hurrell, E., Bennett, K., Congreve, M., Magnani, F. et al. (2011) Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19, 1283-1293
40. Lebon, G., Warne, T., Edwards, P.C., Bennett, K., Langmead, C.J., Leslie, A.G. and Tate, C.G. (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521-525
41. Lebon, G., Edwards, P.C., Leslie, A.G. and Tate, C.G. (2015) Molecular determinants of CGS21680 binding to the human adenosine A2A receptor. Mol. Pharmacol. 87, 907-915
42. Tummino, P.J. and Copeland, R.A. (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492
43. Zhang, R. and Monsma, F. (2009) The importance of drug-target residence time. Curr. Opin. Drug Discov. Dev. 12, 488-496
44. Guo, D., Hillger, J.M., IJzerman, A.P. and Heitman, L.H. (2014) Drug-target residence time - a case for G protein-coupled receptors. Med. Res. Rev. 34, 856-892
45. Kerppola, T.K. (2006) Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat. Protoc. 1, 1278-1286
46. Vidi, P.A. and Watts, V.J. (2009) Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling. Mol. Pharmacol. 75, 733-739
47. Urizar, E., Yano, H., Kolster, R., Galés, C., Lambert, N. and Javitch, J.A. (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat. Chem. Biol. 7, 624-630
48. Banères, J.L. and Parello, J. (2003) Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329, 815-829
49. Hebert, T.E., Moffett, S., Morello, J.P., Loisel, T.P., Bichet, D.G., Barret, C. and Bouvier, M. (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271, 16384-16392
50. Borroto-Escuela, D.O., Romero-Fernandez, W., Tarakanov, A.O., Gómez-Soler, M., Corrales, F., Marcellino, D., Narvaez, M., Frankowska, M., Flajolet, M., Heintz, N. et al. (2010) Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun. 402, 801-807
51. Navarro, G., Quiroz, C., Moreno-Delgado, D., Sierakowiak, A., MacDowell, K., Moreno, E., Aguinaga, D., Rea, W., Cai, N.S., Howel, L.A. et al. (2015) Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine. J. Neurosci. 35, 6639-6653
52. Viñals, X., Moreno, E., Lanfumey, L., Cordomí, A., Pastor, A., de La Torre, R., Gasperini, P., Navarro, G., Howell, L.A., Pardo, L. et al. (2015) Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol. 13, e1002194
53. He, S.Q., Zhang, Z.N., Guan, J.S., Liu, H.R., Zhao, B., Wang, H.B., Li, Q., Yang, H., Luo, J., Li, Z.Y. et al. (2011) Facilitation of m-opioid receptor activity by preventing d-opioid receptor-mediated codegradation. Neuron 69, 120-131
54. Bonaventura, J., Rico, A.J., Moreno, E., Sierra, S., Sanchez, M., Luquin, N., Farre, D., Muller, C.E., Martinez-Pinilla, E., Cortés, A. et al. (2014) L-DOPA-treatment in primates disrupt the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79, 90-100
55. Pinna, A., Bonaventura, J., Farré, D., Sánchez, M., Simola, N., Mallol, J., Lluís, C., Costa, G., Baqi, Y., Müller, C.E. et al. (2014) L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp. Neurol. 253, 180-191